Dupilumab, a therapeutic monoclonal IgG4 antibody, functions in treating AD by binding the IL-4 receptor alpha chain (IL-4Rα), a regulator of type 2 T cell differentiation and a mediator of IL-4/IL-13 cytokine signaling78–80. This evidence concerns the gene IL4R and Alzheimer disease.